ArticleFrontiers in pediatrics2022

Case Report: Everolimus reduced bone turnover markers but showed no clinical benefit in a patient with severe progressive osseous heteroplasia.

M Cebey-López et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.